| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | See Remarks
5 companies
Jerome B Zeldis is Director at STEX, with reported holdings spanning 5 companies. Jerome B Zeldis's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.1M at current prices.
Our model assigns Jerome B Zeldis a below-average insider score of 45/100, based on 8 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -18.0%.
Jerome B Zeldis's largest disclosed position is in PTCT, worth about $1.5M. The PTCT filings lean toward selling, a net 44,000 shares.
Jerome B Zeldis has 51 Form 4 filings on record from April 2015 to October 2026, across 5 companies: Director at Soligenix (SNGX), 2015–2026; Ptc Therapeutics (PTCT), 2016–2026; Director at Nexgel (NXGL), 2021–2025, and 2 more.
The 77 reported transactions were 37 option or other derivative awards, 12 open-market purchases, 8 stock awards and 7 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 12 purchases worth about $187K and 3 sales worth about $2.0M.
The largest open-market purchase was 10,000 shares of SRNE at an average $5.15 on February 3, 2017, about $52K.
The largest open-market sale was 24,000 shares of PTCT at an average $51.50 on December 2, 2024, about $1.2M. Twelve months later PTCT was up 51%.
Both sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | PTCT Ptc Therapeutics, Inc. | Director | Sale+OE10b5-1 | 24,000 | $51.50 | $1,235,897.49 | -62.3% | +1.5% | +50.7% | |
| Nov 20, 2024 | NXGL Nexgel, Inc. | Director | Buy | 3,636 | $2.75 | $9,999.00 | +3.5% | +9.7% | -50.9% | |
| Aug 23, 2024 | NXGL Nexgel, Inc. | Director | Buy | 10,000 | $2.50 | $25,000.00 | +10.7% | +25.8% | -10.8% | |
| May 22, 2024 | PTCT Ptc Therapeutics, Inc. | Director | Sale+OE10b5-1 | 20,000 | $38.24 | $764,800.00 | -58.0% | -11.0% | +17.8% | |
| May 26, 2023 | NXGL Nexgel, Inc. | Director | Buy | 5,000 | $2.34 | $11,688.50 | +5.7% | -6.6% | +2.6% | |
| Mar 25, 2022 | NXGL Nexgel, Inc. | Director | Buy | 5,300 | $1.89 | $10,010.11 | +6.4% | -18.5% | -9.5% | |
| Dec 27, 2021 | NXGL Nexgel, Inc. | Director | Buy | 9,091 | $5.49 | $49,909.59 | +12.3% | -40.0% | -62.5% | |
| May 14, 2021 | SNGX Soligenix, Inc. | Director | Sell | 3,000 | $0.90 | $2,700.60 | -11.6% | +6.1% | -55.3% | |
| May 14, 2021 | SNGX Soligenix, Inc. | Director | Buy | 3,000 | $0.89 | $2,664.00 | +13.1% | +6.1% | -55.3% | |
| May 28, 2020 | STEX Streamex Corp. | Director | Buy | 1,000 | $10.49 | $10,488.90 | +0.9% | - | - |